Chronic kidney disease (CKD) is usually considered to be an irreversible process that often results in end stage renal failure (ESRF), a devastating disorder whose incidence has grown approximately 20-25% during the past decade and accounts about 10% of the total population in the United States. It is unlikely that this high morbidity and associated financial burden will be reduced until we have a better understanding of the molecular and cellular pathogenesis of CKD and develop effective and specific treatment. Interstitial fibrosis, one of the hallmarks of CKD, is generally considered to be the determinant prognosis factor of CKD. In previous in vitro studies, we discovered that p90 ribosomal S6 kinase (p90RSK) promotes LDL receptor- related protein-1 (LRP-1)-mediated interstitial fibroblast proliferation and survival, leading to renal interstitial fibrosis and the progression of CKD. However, the roles of p90RSK and LRP-1 in renal fibrogenesis in vivo have never been investigated. Our central hypothesis is that, in response to chronic kidney injury, the LRP-1 and p90RSK signaling cascade is activated, which promotes renal fibrosis and CKD progression;and that pharmacological inhibition of p90RSK alleviates kidney damage and fibrosis. This hypothesis will be tested by addressing the following specific aims using both in vitro and in vivo approaches:
Specific Aim 1 will determine the role of p90RSK in CKD in the novel inducible fibroblast-specific p90RSK transgenic mice.
Specific Aim 2 will determine the role of LRP-1 in CKD in the unique fibroblast-specific LRP-1 knockout mice.
Specific Aim 3 will determine the therapeutic efficacy of p90RSK inhibition for CKD treatment. The proposed investigations will illuminate novel functions of p90RSK and LRP-1 in renal fibrosis and provide innovative insights into the mechanisms underlying renal fibrogenesis. These studies have translational significance that they will test the therapeutic efficacy of inhibition of p90RSK signaling in the treatment of CKD and will stimulate the development of novel clinical interventions designed to halt or reverse the progression of CKD.
Chronic kidney disease (CKD) is a devastating disease without effective therapies. Inhibition of p90RSK is a novel and promising therapeutic approach for CKD treatment. The proposed studies will examine the role of p90RSK signaling in the pathogenesis of CKD and test the therapeutic efficacy of its specific inhibitor. This proposal will lead to better understanding of the molecular signaling in renal fibrosis and CKD progression, and will be expected to identify more therapeutic strategies and molecular targets for CKD treatment.
|Cao, Yong; Zhang, Duo; Moon, Hyung-Geun et al. (2016) MiR-15a/16 Regulates Apoptosis of Lung Epithelial Cells after Oxidative Stress. Mol Med 22:|
|Chen, Xiang; Shi, Chaowen; Meng, Xiannan et al. (2016) Inhibition of Wnt/Î²-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-Î²1 and FGF-2. Exp Mol Pathol 101:22-30|
|Wang, Cong; Gu, Shen; Cao, Honghui et al. (2016) miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis. Sci Rep 6:30122|
|Wang, Cong; Gu, Shen; Yin, Xiaoqin et al. (2016) The toxic effects of microcystin-LR on mouse lungs and alveolar type II epithelial cells. Toxicon 115:81-8|
|Lin, Ling; Jin, Yang; Hu, Kebin (2015) Tissue-type plasminogen activator (tPA) promotes M1 macrophage survival through p90 ribosomal S6 kinase (RSK) and p38 mitogen-activated protein kinase (MAPK) pathway. J Biol Chem 290:7910-7|
|Lee, Seon-Jin; Zhang, Meng; Hu, Kebin et al. (2015) CCN1 suppresses pulmonary vascular smooth muscle contraction in response to hypoxia. Pulm Circ 5:716-22|
|Lin, Ling; Hu, Kebin (2014) LRP-1: functions, signaling and implications in kidney and other diseases. Int J Mol Sci 15:22887-901|
|Lin, Ling; Jin, Yang; Mars, Wendy M et al. (2014) Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-ÎºB pathways. Am J Pathol 184:2757-67|
|Lin, Ling; Hu, Kebin (2014) Tissue Plasminogen Activator: Side Effects and Signaling. J Drug Des Res 1:|
|Lin, Ling; Hu, Kebin (2014) Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. Am J Clin Exp Immunol 3:30-6|